Home / Health / Immunotherapy Breakthrough: Bowel Cancer Patients Remain Cancer-Free
Immunotherapy Breakthrough: Bowel Cancer Patients Remain Cancer-Free
21 Apr
Summary
- New immunotherapy trial shows patients remained cancer-free for almost three years.
- Pembrolizumab given before surgery proved effective for MMR-deficient bowel cancer.
- Personalized blood tests may help predict treatment response in patients.
Hopes for a bowel cancer cure have been significantly boosted by a groundbreaking clinical trial where patients have remained cancer-free for nearly three years. This new treatment method involves administering the immunotherapy drug pembrolizumab before surgery.
The study focused on 32 patients with stage two or three bowel cancer exhibiting an MMR-deficient/MSI-high genetic profile. Approximately 59% of these patients showed no detectable signs of cancer after surgery, and crucially, none experienced a recurrence within 33 months of follow-up.
Researchers believe this pre-surgery immunotherapy is a significant breakthrough, especially since roughly a quarter of patients receiving standard treatment would typically relapse within three years. The findings suggest that personalized blood tests and immune profiling could soon predict which patients will respond best to this treatment.
One trial participant, 73-year-old Christopher Burston, described the treatment as life-changing, noting that his stage three cancer had effectively "melted away" before surgery. He is now cancer-free and has returned to a normal life.
